Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 80 mg - tablet, modified release - excipient ingredients: copovidone; colloidal anhydrous silica; lactose monohydrate; behenoyl polyoxyglycerides; titanium dioxide; hydrogenated castor oil; stearic acid; magnesium stearate; medium chain triglycerides; maize starch; microcrystalline cellulose; hypromellose; iron oxide black; colour - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - dipyridamole - modified-release capsule - 200mg

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - dipyridamole - modified-release capsule - 200mg

Ισραήλ - Αγγλικά - Ministry of Health

novartis israel ltd - methylphenidate hydrochloride - modified release capsules - methylphenidate hydrochloride 10 mg - methylphenidate - attention deficit hyperactivity disorder (adhd) .

Ισραήλ - Αγγλικά - Ministry of Health

novartis israel ltd - methylphenidate hydrochloride - modified release capsules - methylphenidate hydrochloride 20 mg - methylphenidate - attention deficit hyperactivity disorder (adhd).

Ισραήλ - Αγγλικά - Ministry of Health

novartis israel ltd - methylphenidate hydrochloride - modified release capsules - methylphenidate hydrochloride 30 mg - methylphenidate - attention deficit hyperactivity disorder (adhd).

Ισραήλ - Αγγλικά - Ministry of Health

novartis israel ltd - methylphenidate hydrochloride - modified release capsules - methylphenidate hydrochloride 40 mg - methylphenidate - attention deficit hyperactivity disorder (adhd).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: sodium acetate; magnesium stearate; lactose monohydrate; silicon dioxide; mannitol; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; mannitol; silicon dioxide; hypromellose; magnesium stearate; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: mannitol; hypromellose; sodium acetate; magnesium stearate; lactose monohydrate; silicon dioxide - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.